JP2022552314A5 - - Google Patents

Info

Publication number
JP2022552314A5
JP2022552314A5 JP2022521958A JP2022521958A JP2022552314A5 JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5 JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5
Authority
JP
Japan
Prior art keywords
receptor
cells
domain
chimeric antigen
cd28h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552314A (ja
JP7664913B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2020/054601 external-priority patent/WO2021071962A1/en
Application filed filed Critical
Priority claimed from PCT/US2020/056387 external-priority patent/WO2021077117A1/en
Publication of JP2022552314A publication Critical patent/JP2022552314A/ja
Publication of JP2022552314A5 publication Critical patent/JP2022552314A5/ja
Priority to JP2025063708A priority Critical patent/JP7861191B2/ja
Application granted granted Critical
Publication of JP7664913B2 publication Critical patent/JP7664913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521958A 2019-10-17 2020-10-19 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 Active JP7664913B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063708A JP7861191B2 (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962916468P 2019-10-17 2019-10-17
US62/916,468 2019-10-17
PCT/US2020/054601 WO2021071962A1 (en) 2019-10-07 2020-10-07 Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
USPCT/US2020/054601 2020-10-07
PCT/US2020/056387 WO2021077117A1 (en) 2019-10-17 2020-10-19 Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063708A Division JP7861191B2 (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Publications (3)

Publication Number Publication Date
JP2022552314A JP2022552314A (ja) 2022-12-15
JP2022552314A5 true JP2022552314A5 (cg-RX-API-DMAC10.html) 2023-10-27
JP7664913B2 JP7664913B2 (ja) 2025-04-18

Family

ID=75537569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521958A Active JP7664913B2 (ja) 2019-10-17 2020-10-19 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用
JP2025063708A Active JP7861191B2 (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063708A Active JP7861191B2 (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Country Status (5)

Country Link
US (1) US20240226293A9 (cg-RX-API-DMAC10.html)
EP (1) EP4045539A4 (cg-RX-API-DMAC10.html)
JP (2) JP7664913B2 (cg-RX-API-DMAC10.html)
CN (1) CN114901693A (cg-RX-API-DMAC10.html)
WO (1) WO2021077117A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CA3219160A1 (en) * 2021-05-20 2022-11-24 Robert Kotin Genomic safe harbors
EP4426350A4 (en) * 2021-11-04 2025-09-24 Artiva Biotherapeutics Inc Treatment of cancer with nk cells and multispecific engagers
US20250018034A1 (en) * 2021-11-08 2025-01-16 Fate Therapeutics, Inc. Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CA3247919A1 (en) * 2022-01-11 2023-07-20 Celularity Inc. CD16 CLEFT-RESISTANT CONSTRUCTIONS AND THEIR USES
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
WO2024140778A1 (zh) * 2022-12-27 2024-07-04 科济生物医药(上海)有限公司 Nkg2d工程化细胞及其组合物
CN116445414B (zh) * 2023-03-03 2025-07-08 广州瑞臻再生医学科技有限公司 基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用
CN117285651B (zh) * 2023-09-27 2025-06-06 中国医学科学院北京协和医院 靶向c-MET的嵌合抗原受体、CAR-M及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CN122146606A (zh) * 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US11578115B2 (en) * 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
AU2020437669A1 (en) * 2020-03-26 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD28H domain-containing chimeric antigen receptors and methods of use

Similar Documents

Publication Publication Date Title
JP2022550899A5 (cg-RX-API-DMAC10.html)
JP2022541441A5 (cg-RX-API-DMAC10.html)
JP2021505131A5 (cg-RX-API-DMAC10.html)
JP2022548943A5 (cg-RX-API-DMAC10.html)
JP2021519061A5 (cg-RX-API-DMAC10.html)
JP2023549098A5 (cg-RX-API-DMAC10.html)
JP2022176327A (ja) タグ化キメラエフェクター分子およびそのレセプター
JP2022510207A5 (cg-RX-API-DMAC10.html)
JP2023505206A5 (cg-RX-API-DMAC10.html)
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
US11845804B2 (en) CAR-CD30 T cells for treatment of CD30+ tumors
JP2023530704A5 (cg-RX-API-DMAC10.html)
JP2023548467A5 (cg-RX-API-DMAC10.html)
JP7566628B2 (ja) キメラ抗原受容体を発現する免疫細胞
US11065278B2 (en) Method and compositions for cellular immunotherapy
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
JP2023548829A5 (cg-RX-API-DMAC10.html)
JP2018532432A5 (cg-RX-API-DMAC10.html)
US12187776B2 (en) Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
JP2021536265A5 (cg-RX-API-DMAC10.html)
JP2023501722A5 (cg-RX-API-DMAC10.html)
WO2018002358A1 (en) Improved adoptive t-cell therapy
GB2607452A (en) Anti-TCR antibody molecules and uses thereof
JP2025105605A5 (cg-RX-API-DMAC10.html)
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도